2-(benzofuran-3-yl)acetamide | 187804-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-(benzofuran-3-yl)acetamide
• 英文别名: (benzofuran-3-yl)acetamide；2-benzofuran-3-ylacetamide；benzofuran-3-yl-acetic acid amide；Benzofuran-3-yl-essigsaeure-amid；2-benzofuran-3-yl-acetamide；benzofuran-3-acetamide；2-(1-benzofuran-3-yl)acetamide
• CAS: 187804-19-9
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: PUMZAZRAXLZJEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(benzofuran-3-yl)acetamide 在 氢氧化钾 作用下， 生成 苯并呋喃-3-乙酸
  参考文献：
  名称：

  合成香豆酮-3-羰基合成酯和合成香豆酰基-3-乙酰基合成

  摘要：

  DOI：

  10.1002/hlca.193702001127
• 作为产物：
  描述：

  (2-carboxymethoxy-phenyl)-glyoxylic acid 在 ammonium hydroxide 、 氯化亚砜 、 乙醚 、 乙醇 、 sodium 、 silver nitrate 作用下， 生成 2-(benzofuran-3-yl)acetamide
  参考文献：
  名称：

  合成香豆酮-3-羰基合成酯和合成香豆酰基-3-乙酰基合成

  摘要：

  DOI：

  10.1002/hlca.193702001127

文献信息

• HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Gavish Moshe

  公开号：US20100029658A1

  公开（公告）日：2010-02-04

  The present invention relates to novel quinoxaline, quinazoline and phthalazine derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in treating and preventing neurodegenerative diseases.

  本发明涉及新型喹喔啉、喹喔啉和邻苯二甲酰苯胺衍生物，以及多聚衍生物，其制备方法，包括这些化合物的制药组合物，以及利用这些化合物治疗和预防由脑损伤引起的脑损伤，特别是由创伤性脑损伤（TBI）引起的继发性脑损伤的方法。本发明的化合物还可用于治疗和预防神经退行性疾病。
• Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors
  申请人：KOZIKOWSKI Alan P.

  公开号：US20100004308A1

  公开（公告）日：2010-01-07

  Compounds of formula: and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy, motor neuron disease, cranial or spinal trauma, neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer's disease, Fragile X syndrome, autism, Huntington's disease, Parkinson's disease, amylotrophic lateral sclerosis (ALS), AIDS-associated dementia, diabetes, particularly type II diabetes, cardiomycete hypertrophy, reperfusion/ischemia, cancer, particularly colorectal cancer, pancreatic cancer, allergies and/or asthma and hair loss or baldness.

  该化合物的公式：以及其药学上可接受的盐、酯和溶剂化物，其中变量在说明书中定义，通常用作蛋白激酶抑制剂，特别是用于抑制GSK-3。提供了含有发明化合物的药学组合物和药物。本发明提供了治疗蛋白激酶相关疾病、紊乱或病况的方法。本发明提供了治疗GSK-3相关疾病、紊乱或病况的方法。更具体地，本发明提供了治疗双相情感障碍、包括躁狂、精神分裂症、中风、癫痫、运动神经元疾病、头部或脊柱创伤、神经退行性疾病、包括多发性硬化症（MS）、阿尔茨海默病、脆性X综合征、自闭症、亨廷顿病、帕金森病、肌萎缩性脊髓侧索硬化症（ALS）、艾滋病相关痴呆、糖尿病，特别是II型糖尿病、心肌肥厚、复灌/缺血、癌症，特别是结肠癌、胰腺癌、过敏和/或哮喘以及脱发或秃发的方法。
• DRUGS INHIBITING CELL DEATH
  申请人：SAGAMI CHEMICAL RESEARCH CENTER

  公开号：EP1224932A1

  公开（公告）日：2002-07-24

  A cell death inhibitor, a pharmaceutical or a preservative for organs, tissues or cells, a comprising, as an active ingredient, an indolylmaleimide derivative represented by the following formula (I), which is useful for inhibiting death of cells, the drug being expected as a preventive or a remedy for the progress of various diseases wherein cell death participates in progress and exacerbation thereof:

  一种细胞死亡抑制剂，一种用于器官、组织或细胞的药物或防腐剂，其有效成分包括由下式（I）代表的吲哚马来酰亚胺衍生物，该衍生物可用于抑制细胞死亡，该药物可望作为各种疾病的预防或治疗药物，在这些疾病中，细胞死亡参与了疾病的进展和恶化：
• Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR)
  申请人：Technion Research & Development Foundation

  公开号：EP2589597A2

  公开（公告）日：2013-05-08

  The present invention relates to quinazoline derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in treating and preventing neurodegenerative diseases.

  本发明涉及喹唑啉衍生物以及多聚衍生物、其制备方法、包括此类化合物的药物组合物，以及使用这些化合物治疗和预防脑损伤导致的脑损伤，特别是创伤性脑损伤（TBI）导致的继发性脑损伤的方法。本发明的化合物还可用于治疗和预防神经退行性疾病。
• Structure-Based Design Leads to the Identification of Lithium Mimetics That Block Mania-like Effects in Rodents. Possible New GSK-3β Therapies for Bipolar Disorders
  作者：Alan P. Kozikowski、Irina N. Gaisina、Hongbin Yuan、Pavel A. Petukhov、Sylvie Y. Blond、Allison Fedolak、Barbara Caldarone、Paul McGonigle

  DOI：10.1021/ja068969w

  日期：2007.7.1

  More than two million American adults, or approximately one percent of the population 18 years or older, suffer from bipolar disorder. Current treatments include the so-called "mood stabilizers," lithium and valproic acid. Both are relatively dated drugs that are only partially effective and produce various undesirable side effects including weight gain. Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3 beta (GSK-3 beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders. Furthermore, the pro-apoptotic properties of the GSK-3 enzyme suggest the possible use of such inhibitors as neuroprotective agents. In fact, neuroprotection may contribute to the treatment of mood disorders. The present chemistry, modeling, and biology efforts have identified 3-benzofuranyl-4-indolylmaleimides as potent and relatively selective GSK-3 beta inhibitors. The best ligand in this series (having a K-i value of 4.6 nM against GSK-3 beta) was studied in a novel mouse model of mania that has recently been validated with several clinically effective mood stabilizers. This study presents the first demonstration of the efficacy of a GSK-3 beta inhibitor in this mouse model of mania. Selective brain penetrable GSK-3 ligands like those described herein become valuable research tools in better defining the role of this multifaceted kinase in both physiological and pathophysiological events.